Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 7, 2016, Pages 1197-1205

  Flowers, Christopher R ^a   Costa, Luciano J ^b   Pasquini, Marcelo C ^c   Le Rademacher, Jennifer ^c   Lill, Michael ^d   Shore, Tsiporah B ^e   Vaughan, William ^f   Craig, Michael ^g   Freytes, Cesar O ^h   Shea, Thomas C ⁱ   Horwitz, Mitchell E ^j   Fay, Joseph W ^k   Mineishi, Shin ^l   Rondelli, Damiano ^m   Mason, James ⁿ   Braunschweig, Ira ^o   Ai, Weiyun ^p   Yeh, Rosa F ^q   Rodriguez, Tulio E ^r   Flinn, Ian ^s   Comeau, Terrance ^t   Yeager, Andrew M ^u   Pulsipher, Michael A ^v   Bence Bruckler, Isabelle ^w   Laneuville, Pierre ^x   Bierman, Philip ^y   Chen, Andy I ^z   Kato, Kazunobu ^aa   Wang, Yanlin ^aa   Xu, Cong ^aa   Smith, Angela J ^aa   Waller, Edmund K ^a   more..

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e WEILL CORNELL MEDICAL CENTER   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g WEST VIRGINIA UNIVERSITY   (United States)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

^k BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^l UNIVERSITY OF MICHIGAN   (United States)

^m UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

ⁿ SCRIPPS CLINIC   (United States)

^o MONTEFIORE MEDICAL CENTER   (United States)

^p UNIVERSITY OF CALIFORNIA   (United States)

^q SEATTLE CANCER CARE ALLIANCE   (United States)

^r LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^s SARAH CANNON RESEARCH INSTITUTE   (United States)

^t New Brunswick Stem Cell Transplant Program   (Canada)

^u UNIVERSITY OF ARIZONA   (United States)

^v UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^w UNIVERSITY OF OTTAWA   (Canada)

^x ROYAL VICTORIA HOSPITAL   (Canada)

^y UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^z OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^aa OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

more..

Author keywords

Autologous stem cell transplantation; Busulfan; Chemotherapy; Hodgkin lymphoma; Lymphoma; Non Hodgkin lymphoma; Stem cell transplantation

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; COMPARATIVE STUDY; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGITIS; FAINTNESS; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOXIA; LARGE CELL LYMPHOMA; LIVER VENOOCCLUSIVE DISEASE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MORTALITY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PATIENT SAFETY; PHARMACOKINETIC PARAMETERS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; STOMATITIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; AUTOTRANSPLANTATION; CLINICAL TRIAL; DRUG COMBINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; NORTH AMERICA; PROCEDURES; SURVIVAL ANALYSIS;

ADULT; AGED; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DRUG COMBINATIONS; ETOPOSIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MELPHALAN; MIDDLE AGED; NORTH AMERICA; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 84975229745     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2016.03.018     Document Type: Article

References (51)

1. Bains T., Chen A.I., Lemieux A., et al. Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma 2014, 55:583-587.
2. Josting A., Muller H., Borchmann P., et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol 2010, 28:5074-5080.
3. Linch D.C., Winfield D., Goldstone A.H., et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993, 341:1051-1054.
4. Santos E.C., Sessions J., Hutcherson D., et al. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation-a similar experience. Biol Blood Marrow Transplant 2007, 13:746-747.
5. Lazarus H.M., Carreras J., Boudreau C., et al. Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center for International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant 2008, 14:1323-1333.
6. McCarthy P.L., Hahn T., Hassebroek A., et al. Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. Biol Blood Marrow Transplant 2013, 19:1116-1123.
7. Ulrickson M., Aldridge J., Kim H.T., et al. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. Biol Blood Marrow Transplant 2009, 15:1447-1454.
8. Flowers C.R., Armitage J.O. A decade of progress in lymphoma: advances and continuing challenges. Clin Lymphoma Myeloma Leuk 2010, 10:414-423.
9. Moskowitz A.J., Moskowitz C.H. Controversies in the treatment of lymphoma with autologous transplantation. Oncologist 2009, 14:921-929.
10. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
11. Schouten H.C., Qian W., Kvaloy S., et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003, 21:3918-3927.
12. Van Besien K. The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood Rev 2006, 20:235-244.
13. Nastoupil L.J., Shenoy P.J., Ambinder A., et al. Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. Leuk Lymphoma 2015, 56:383-389.
14. Schmitz N., Nickelsen M., Ziepert M., et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 2012, 13:1250-1259.
15. Stiff P.J., Unger J.M., Cook J.R., et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 2013, 369:1681-1690.
16. Cortelazzo S., Rossi A., Viero P., et al. BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma. Br J Haematol 1997, 99:379-385.
17. Flowers C.R., Sinha R., Vose J.M. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin 2010, 60:393-408.
18. Haioun C., Mounier N., Emile J.F., et al. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol 2009, 20:1985-1992.
19. Glossmann J.P., Josting A., Pfistner B., et al. A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2). Ann Hematol 2002, 81:424-429.
20. Jo J.C., Kang B.W., Jang G., et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol 2008, 87:43-48.
21. Shimoni A., Avivi I., Rowe J.M., et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer 2012, 118:4706-4714.
22. Vose J.M., Carter S., Burns L.J., et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol 2013, 31:1662-1668.
23. Gutierrez-Delgado F., Maloney D.G., Press O.W., et al. Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens. Bone Marrow Transplant 2001, 28:455-461.
24. Kim J.E., Lee D.H., Yoo C., et al. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leuk Res 2011, 35:183-187.
25. Aggarwal C., Gupta S., Vaughan W.P., et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant 2006, 12:770-777.
26. Andion M., Molina B., Gonzalez-Vicent M., et al. High-dose busulfan and cyclophosphamide as a conditioning regimen for autologous peripheral blood stem cell transplantation in childhood non-Hodgkin lymphoma patients: a long-term follow-up study. J Pediatr Hematol Oncol 2011, 33:e89-e91.
27. Dean R.M., Pohlman B., Sweetenham J.W., et al. Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide. Br J Haematol 2010, 148:226-234.
28. Grigg A.P., Stone J., Milner A.D., et al. Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma. Leuk Lymphoma 2010, 51:641-649.
29. Lane A.A., McAfee S.L., Kennedy J., et al. High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma. Leuk Lymphoma 2011, 52:1363-1366.
30. Zhang H., Graiser M., Hutcherson D.A., et al. Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:1287-1294.
31. Beri R., Chunduri S., Sweiss K., et al. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. Bone Marrow Transplant 2010, 45:249-253.
32. Lazarus H.M., Zhang M.J., Carreras J., et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant 2010, 16:35-45.
33. Pasquini MC, Wang Z, Horowitz MM, Gale RP. 2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clinical Transplants. 2010:87-105. Los Angeles, CA: The Terasaki Foundation Laboratory; 2011.
34. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
35. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329:987-994.
36. Costa L.J., Lill M., Yeh R.F., et al. Safety of PK-guided IV Bu Cy VP-16 preparative regimen prior to autologous hematopoietic stem cell transplantation for lymphoma: findings from a multi-center phase II study in North America. ASH Annual Meet Abstr 2012, 120:813.
37. Madden T., de Lima M., Thapar N., et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant 2007, 13:56-64.
38. Vaughan W.P., Carey D., Perry S., et al. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. Biol Blood Marrow Transplant 2002, 8:619-624.
39. Ryu S.G., Lee J.H., Choi S.J., et al. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007, 13:1095-1105.
40. Yeh R.F., Pawlikowski M.A., Blough D.K., et al. Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2012, 18:265-272.
41. Slattery J.T., Risler L.J. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 1998, 20:543-549.
42. Milpied N., Deconinck E., Gaillard F., et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004, 350:1287-1295.
43. Lee E., Wei L., Amato D. Cox-type regression analysis for large numbers of small groups of correlated failure time observations. Survival analysis: state of the art 1992, 237-247. Kluwer Academic, Norwell, MA. J. Klein, P. Goel (Eds.).
44. Jones R.J., Lee K.S., Beschorner W.E., et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987, 44:778-783.
45. Beri R., Chunduri S., Sweiss K., Peace D.J., Mactal-Haaf C., Dobogai L.C., Shord S., Quigley J.G., Chen Y.H., Mahmud N., Rondelli D. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. Bone Marrow Transplant 2010, 45:249-253.
46. Kletzel M., Jacobsohn D., Duerst R. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:472-479.
47. Kangarloo S.B., Naveed F., Ng E.S., et al. Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing. Biol Blood Marrow Transplant 2012, 18:295-301.
48. Wang Y., Kato K., Le Gallo C., et al. Dosing algorithm revisit for busulfan following IV infusion. Cancer Chemother Pharmacol 2015, 75:505-512.
49. Kebriaei P., Madden T., Kazerooni R., et al. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biol Blood Marrow Transplant 2011, 17:412-420.
50. Wang E.H., Chen Y.A., Corringham S., et al. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant 2004, 34:581-587.
51. Chen Y.-B., Li S., Fisher D.C., et al. Phase II trial of tandem high-dose chemotherapy with autologous stem cell transplantation followed by reduced-intensity allogeneic stem cell transplantation for patients with high-risk lymphoma. Biol Blood Marrow Transplant 2015, 21:1583-1588.